Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
- Author
- ANTONI, Christian E1 ; KAVANAUGH, Arthur2 ; MANGER, Bernhard1 ; WASSENBERG, Siegfried8 ; WEIER, Ralf8 ; WALLACE, Daniel J9 ; WEISMAN, Michael H9 ; KALDEN, Joachim R1 ; SMOLEN, Josef10 ; KIRKHAM, Bruce3 ; TUTUNCU, Zuhre2 ; BURMESTER, Gerd R4 ; SCHNEIDER, Udo4 ; FURST, Daniel E5 ; MOLITOR, Jerry6 ; KEYSTONE, Edward7 ; GLADMAN, Dafna7
[1] Friedrich-Alexander University, Erlangen-Nuremberg, Germany
[2] Center for Innovative Therapy, University of California, San Diego, United States
[3] Guy's Hospital, London, United Kingdom
[4] Charité University Hospital, Berlin, Germany
[5] University of California, Los Angeles, United States
[6] Virginia Mason Clinic, Seattle, Washington, United States
[7] University of Toronto, Toronto, Ontario, Canada
[8] Evangelisches Fachkrankenhaus, Ratingen, Germany
[9] Cedars-Sinai Medical Center, Los Angeles, California, United States
[10] Medical University of Vienna and Lainz Hospital, Vienna, Austria - Source
Arthritis and rheumatism. 2005, Vol 52, Num 4, pp 1227-1236, 10 p ; ref : 36 ref
- CODEN
- ARHEAW
- ISSN
- 0004-3591
- Scientific domain
- Rheumatology
- Publisher
- Wiley, Hoboken , NJ
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Chronique Immunodépresseur Immunomodulateur Infliximab Peau pathologie Psoriasis Rhumatisme psoriasique Traitement Anticorps monoclonal Anticytokine Rhumatisme inflammatoire Spondylarthropathie Système ostéoarticulaire pathologie
- Keyword (en)
- Chronic Immunosuppressive agent Immunomodulator Infliximab Skin disease Psoriasis Psoriatic arthritis Treatment Monoclonal antibody Anticytokine Inflammatory joint disease Spondylarthropathy Diseases of the osteoarticular system
- Keyword (es)
- Crónico Inmunodepresor Inmunomodulador Infliximab Piel patología Psoriasis Reumatismo psoriásico Tratamiento Anticuerpo monoclonal Anticitoquina Reumatismo inflamatorio Espondilartropatia Sistema osteoarticular patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02Q Immunomodulators
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B08 Dermatology / 002B08D Psoriasis. Parapsoriasis. Lichen
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B15 Diseases of the osteoarticular system / 002B15D Inflammatory joint diseases
- Discipline
- Dermatology Osteoarticular pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16769137
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1002/art.20967 
https://dx.doi.org/10.1002/art.20967
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/art.20967\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Arthritis and rheumatism\";s:9:\"\u0000*\u0000stitle\";s:15:\"Arthritis rheum\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1227\";s:8:\"\u0000*\u0000epage\";s:4:\"1236\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0004-3591\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ANTONI\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Christian E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:17:\"KAVANAUGH, Arthur\";i:1;s:16:\"MANGER, Bernhard\";i:2;s:21:\"WASSENBERG, Siegfried\";i:3;s:11:\"WEIER, Ralf\";i:4;s:17:\"WALLACE, Daniel J\";i:5;s:18:\"WEISMAN, Michael H\";i:6;s:17:\"KALDEN, Joachim R\";i:7;s:13:\"SMOLEN, Josef\";i:8;s:14:\"KIRKHAM, Bruce\";i:9;s:14:\"TUTUNCU, Zuhre\";i:10;s:17:\"BURMESTER, Gerd R\";i:11;s:14:\"SCHNEIDER, Udo\";i:12;s:15:\"FURST, Daniel E\";i:13;s:14:\"MOLITOR, Jerry\";i:14;s:16:\"KEYSTONE, Edward\";i:15;s:14:\"GLADMAN, Dafna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHEAW\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:8:\"\u0000*\u0000place\";s:12:\"Hoboken , NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/art.20967\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Arthritis and rheumatism\";s:9:\"\u0000*\u0000stitle\";s:15:\"Arthritis rheum\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1227\";s:8:\"\u0000*\u0000epage\";s:4:\"1236\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0004-3591\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ANTONI\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Christian E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:17:\"KAVANAUGH, Arthur\";i:1;s:16:\"MANGER, Bernhard\";i:2;s:21:\"WASSENBERG, Siegfried\";i:3;s:11:\"WEIER, Ralf\";i:4;s:17:\"WALLACE, Daniel J\";i:5;s:18:\"WEISMAN, Michael H\";i:6;s:17:\"KALDEN, Joachim R\";i:7;s:13:\"SMOLEN, Josef\";i:8;s:14:\"KIRKHAM, Bruce\";i:9;s:14:\"TUTUNCU, Zuhre\";i:10;s:17:\"BURMESTER, Gerd R\";i:11;s:14:\"SCHNEIDER, Udo\";i:12;s:15:\"FURST, Daniel E\";i:13;s:14:\"MOLITOR, Jerry\";i:14;s:16:\"KEYSTONE, Edward\";i:15;s:14:\"GLADMAN, Dafna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHEAW\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:8:\"\u0000*\u0000place\";s:12:\"Hoboken , NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/art.20967\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/art.20967\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Arthritis and rheumatism\";s:9:\"\u0000*\u0000stitle\";s:15:\"Arthritis rheum\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1227\";s:8:\"\u0000*\u0000epage\";s:4:\"1236\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0004-3591\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ANTONI\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Christian E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:17:\"KAVANAUGH, Arthur\";i:1;s:16:\"MANGER, Bernhard\";i:2;s:21:\"WASSENBERG, Siegfried\";i:3;s:11:\"WEIER, Ralf\";i:4;s:17:\"WALLACE, Daniel J\";i:5;s:18:\"WEISMAN, Michael H\";i:6;s:17:\"KALDEN, Joachim R\";i:7;s:13:\"SMOLEN, Josef\";i:8;s:14:\"KIRKHAM, Bruce\";i:9;s:14:\"TUTUNCU, Zuhre\";i:10;s:17:\"BURMESTER, Gerd R\";i:11;s:14:\"SCHNEIDER, Udo\";i:12;s:15:\"FURST, Daniel E\";i:13;s:14:\"MOLITOR, Jerry\";i:14;s:16:\"KEYSTONE, Edward\";i:15;s:14:\"GLADMAN, Dafna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHEAW\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:8:\"\u0000*\u0000place\";s:12:\"Hoboken , NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/art.20967\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Arthritis and rheumatism\";s:9:\"\u0000*\u0000stitle\";s:15:\"Arthritis rheum\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1227\";s:8:\"\u0000*\u0000epage\";s:4:\"1236\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0004-3591\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ANTONI\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Christian E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:17:\"KAVANAUGH, Arthur\";i:1;s:16:\"MANGER, Bernhard\";i:2;s:21:\"WASSENBERG, Siegfried\";i:3;s:11:\"WEIER, Ralf\";i:4;s:17:\"WALLACE, Daniel J\";i:5;s:18:\"WEISMAN, Michael H\";i:6;s:17:\"KALDEN, Joachim R\";i:7;s:13:\"SMOLEN, Josef\";i:8;s:14:\"KIRKHAM, Bruce\";i:9;s:14:\"TUTUNCU, Zuhre\";i:10;s:17:\"BURMESTER, Gerd R\";i:11;s:14:\"SCHNEIDER, Udo\";i:12;s:15:\"FURST, Daniel E\";i:13;s:14:\"MOLITOR, Jerry\";i:14;s:16:\"KEYSTONE, Edward\";i:15;s:14:\"GLADMAN, Dafna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHEAW\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:8:\"\u0000*\u0000place\";s:12:\"Hoboken , NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/art.20967\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Arthritis and rheumatism\";s:9:\"\u0000*\u0000stitle\";s:15:\"Arthritis rheum\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1227\";s:8:\"\u0000*\u0000epage\";s:4:\"1236\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0004-3591\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ANTONI\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Christian E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:17:\"KAVANAUGH, Arthur\";i:1;s:16:\"MANGER, Bernhard\";i:2;s:21:\"WASSENBERG, Siegfried\";i:3;s:11:\"WEIER, Ralf\";i:4;s:17:\"WALLACE, Daniel J\";i:5;s:18:\"WEISMAN, Michael H\";i:6;s:17:\"KALDEN, Joachim R\";i:7;s:13:\"SMOLEN, Josef\";i:8;s:14:\"KIRKHAM, Bruce\";i:9;s:14:\"TUTUNCU, Zuhre\";i:10;s:17:\"BURMESTER, Gerd R\";i:11;s:14:\"SCHNEIDER, Udo\";i:12;s:15:\"FURST, Daniel E\";i:13;s:14:\"MOLITOR, Jerry\";i:14;s:16:\"KEYSTONE, Edward\";i:15;s:14:\"GLADMAN, Dafna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARHEAW\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:199:\"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis : Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)\";s:8:\"\u0000*\u0000place\";s:12:\"Hoboken , NJ\";s:6:\"\u0000*\u0000pub\";s:5:\"Wiley\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
